NKTX
Nkarta, Inc.Healthcare·Biotechnology
$3.25
$233M market cap
Revenue
$0.0M
Free Cash Flow
$-50.8M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute my
2-Year Price History
$3.03-54.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -28.5 | -30.9 | -27.8 | -28.2 | -28.6 | -0.4 | 230.4 | 75.0 | 74.3 | -83.2% | -- | -- |
| Act | 2025-Q4 | 0.0 | -28.7 | -31.0 | -27.4 | -21.7 | -22.2 | -0.6 | 276.3 | 76.4 | 74.0 | -69.6% | -- | -- |
Valuation & Metrics
Market Stats
Price$3.25
Market Cap$233M
Enterprise Value$77M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-21.9%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-55.2M
Free Cash Flow$-50.8M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-76.4%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares5.3M
Days to Cover3.9
Change (vs Prior)-2.5%
Need at least 2 settlement dates for chart
Employees
Headcount157
Revenue / Employee$0
Gross Profit / Employee$-14,904
Cash Runway
54.4months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
45.6%(+2.5% YoY)
108 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
10.1%(+1.3% YoY)
10 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.0% YoY)
7 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $22.8M | $11.45 | +$0 | +$0 | -4.2% | $9.44B |
| BlackRock, Inc.Passive | $9.5M | $3.98 | +$830K | −$44K | -0.2% | $5.69T |
| NEA Management Company, LLC | $7.5M | $12.32 | +$0 | +$0 | -3.4% | $1.76B |
| Samsara BioCapital, LLC | $7.4M | $11.54 | +$0 | −$549K | -3.5% | $1.03B |
| SR ONE CAPITAL MANAGEMENT, LP | $7.0M | $11.41 | +$0 | +$0 | -7.2% | $915M |
| GSK plc | $6.6M | $1.85 | +$0 | +$6.6M | -21.9% | $599M |
| Monaco Asset Management SAM | $5.3M | $1.78 | −$53K | +$3.6M | +1.9% | $315M |
| Alyeska Investment Group, L.P. | $4.4M | $2.78 | +$0 | +$42K | -0.5% | $35.33B |
| TWO SIGMA INVESTMENTS, LP | $4.3M | $4.18 | +$2.3M | +$3.9M | -0.9% | $117.03B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $4.2M | $2.11 | +$4.2M | +$4.2M | — | $4.04T |
| CITADEL ADVISORS LLC | $3.8M | $5.68 | +$926K | −$3.6M | -0.4% | $138.22B |
| RENAISSANCE TECHNOLOGIES LLC | $3.7M | $4.11 | +$64K | +$1.9M | +1.2% | $63.91B |
| WASATCH ADVISORS INC | $3.3M | $5.67 | +$3K | −$1.0M | -2.9% | $14.87B |
| TANG CAPITAL MANAGEMENT LLC | $3.1M | $3.24 | +$0 | −$11.8M | -5.5% | $1.93B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $2.7M | $7.59 | +$240K | +$147K | +2.3% | $1.61T |
| ACADIAN ASSET MANAGEMENT LLC | $2.7M | $3.10 | +$1.2M | +$1.3M | -0.5% | $70.48B |
| STATE STREET CORPPassive | $2.6M | $10.75 | +$144K | +$252K | -0.2% | $2.89T |
| AWM Investment Company, Inc. | $1.9M | $2.89 | +$0 | −$198K | -0.6% | $903M |
| Peapod Lane Capital LLC | $1.4M | $1.83 | +$0 | +$162K | -0.8% | $122M |
| AQR CAPITAL MANAGEMENT LLC | $1.3M | $2.78 | +$584K | −$161K | -0.2% | $218.19B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-3.86%
avg per quarter
Holders (ex-self)
-3.77%
excl. this stock
Buyers (this Q)
-0.56%
63 buyers · $0.02B in
Sellers (this Q)
-2.14%
33 sellers · $0.00B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+1.4%
how holders react when this stock falls
On quiet Qs
+21.5%
−10% to +10% baseline
On rallies (+10%+)
+19.0%
how they react when this stock rises
Holders' portfolio flow this Q
+5.4%
inflows — adds are organic
Sellers' portfolio flow this Q
+18.5%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.1%
Holder mid (any stock)
-3.1%
Holder rally (any stock)
-6.3%
Biggest decreases this quarter
Blackstone Group L.P.exited−$1.4MMARSHALL WACE, LLPexited−$287KMonaco Asset Management SAM−$53Kα+1.9JPMORGAN CHASE & CO−$51Kα-0.2Quadrature Capital Ltdexited−$41KSG Americas Securities, LLCexited−$39KDynamic Technology Lab Private Ltdexited−$37KHRT FINANCIAL LPexited−$32KRAYMOND JAMES FINANCIAL INCexited−$20KBOURGEON CAPITAL MANAGEMENT LLCexited−$19K
New buyers this quarter
Top-5 holders · 44.6%
RA CAPITAL MANAGEMENT, L.P.--
BlackRock, Inc.--
NEA Management Company, LLC--
Samsara BioCapital, LLC--
SR ONE CAPITAL MANAGEMENT, LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.10.8MNEA Management Company, LLC3.6MNovo Holdings A/S—Samsara BioCapital, LLC3.5MBoxer Capital, LLC—DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)—T. Rowe Price Investment Management, Inc.—PRICE T ROWE ASSOCIATES INC /MD/29KADAGE CAPITAL PARTNERS GP, L.L.C.—Deep Track Capital, LP—
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$9.0017690.0%
Last Year (1 analysts)$9.0017690.0%
Current Price$3.25
Analyst Ratings
1
9
2
Strong Buy: 1Buy: 9Hold: 2Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$69K
3 txns · 2 insiders · 33,485 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-01-15 | SELL | HASTINGS PAUL J | director, officer: Chief Executive Officer | 26,046 | $2.07 | $54K | $807K |
| 2026-01-15 | SELL | Mahmood Nadir | officer: President | 5,649 | $2.07 | $12K | $347K |
| 2025-06-18 | SELL | HASTINGS PAUL J | director, officer: Chief Executive Officer | 1,790 | $1.79 | $3K | $573K |
Order Flow (FINRA, ~3w lag)
41.7%retail+2.0pp
9.9%dark-3.3pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Nkarta, Inc.: Strategic Retrenchment and Market Cap Erosion Under Forensic Scrutiny
Overall Risk
7/10
Fraud
2/10
Dilution
8/10
Insolvency
4/10
Earnings Overstated
3/10
Hidden Liabilities
3/10
Legal
2/10
Audit Warnings
4/10
Hidden Upside
3/10
Contextually Acceptable
6/10